The goal of this clinical trial was to evaluate the effectiveness of a low glycemic index diet (LGID) on seizure frequency, oxidative stress markers and quality of life in children with drug-resistant epilepsy. Based upon the aims, the following hypotheses were tested: 1. LGID reduces seizure frequency in children with drug-resistant epilepsy. 2. LGID improves oxidative parameters in children with drug-resistant epilepsy 3. LGID improves quality of life and mental health in children with drug-resistant epilepsy Participants were prescribed the LGID for 3 months.At baseline and at outpatient clinic follow-ups at 3 months, anthropometric measurements were taken, the strengths and difficulties questionnaire (SDQ), Pediatric Inventory of Quality of Life (PedsQL) and depression scales were administered and samples for biochemical measurements were collected. Diet compliance was evaluated by food consumption records during monthly follow-up visits (at 1 , 2, and 3 months).
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Changes in seizure frequency
Timeframe: Baseline and Month 3
Concentration of antioxidant and oxidant status
Timeframe: Baseline and Month 3
Concentration of Paraoxonase Enzyme Activity
Timeframe: Baseline and Month 3
Concentration of Malondialdehyde (MDA)
Timeframe: Baseline and Month 3
Changes in quality of life
Timeframe: Baseline and Month 3
Changes in psychosocial problems
Timeframe: Baseline and Month 3
Changes in depression level
Timeframe: Baseline and Month 3